Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 14, 22 | -0.56
Decreased by
-115.38%
|
-0.50
Decreased by
-12.00%
|
Aug 15, 22 | -0.49
Increased by
+97.94%
|
-0.45
Decreased by
-8.89%
|
May 16, 22 | -0.45 | -0.28
Decreased by
-60.71%
|
Mar 30, 22 | -0.35 | -0.31
Decreased by
-12.90%
|
Nov 15, 21 | -0.26 | -0.26 |
Aug 16, 21 | -23.80 | -0.16
Decreased by
-14.78 K%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-13.59 M
Decreased by
-119.73%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-11.99 M
Decreased by
-107.64%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-10.91 M
Decreased by
-292.30%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
N/A%
|
-8.70 M
Decreased by
-137.23%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-6.18 M
Decreased by
-168.05%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
N/A%
|
-5.78 M
Decreased by
-162.26%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 21 | 0.00
Decreased by
N/A%
|
-2.78 M
Decreased by
-93.66%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 20 | 0.00 - | -3.67 M - |
Decreased by
N/A%
-
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.